Novartis NVS announced that the FDA has approved Fabhalta (iptacopan) for a third indication. The regulatory body approved ...

Bridge the gap between uncertainty and action with insights into symptoms that warrant immediate medical attention.

Savaysa is intended for use to reduce the risk of stroke and systemic embolism in individuals who have atrial fibrillation. It is also taken to treat DVT and pulmonary embolism. Savaysa is classified ...

Pulmonary embolism is a common cause of cardiovascular-associated morbidity and mortality. Although pulmonary embolism ...

Some have developed other conditions, which they suspect is linked to Covid because they were in fine health before it. To ...

Since 1926, dividends have contributed approximately 32% of the total return for the S&P 500, while capital appreciation has contributed 68%. Therefore, sustainable dividend income and capital ...

In December 2024, the National Comprehensive Cancer Network® (NCCN) added AUCATZYL (obecabtagene autoleucel) to its Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for the treatment of ...

Received European Commission approval for GOHIBIC® (vilobelimab) for the treatment of SARS-CoV-2-induced acute respiratory distress syndrome ...

U.S. commercial launch progressing on track with 33 authorized treatment centers as of March 19, 2025, following US FDA approval on November 8, 2024Obe-cel MHRA and ...

France’s Council of State rejects contention by campaigners that racial profiling by police is systemic Local grassroots organizations and international rights groups had hoped that a favorable ...

Purpose The pharmacology, pharmacokinetics, efficacy, and safety of apixaban are reviewed. Summary Apixaban is an oral, direct, selective factor Xa inhibitor with a rapid onset of action. It has a ...